

Farrukh T Awan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8049479/publications.pdf>

Version: 2024-02-01

208
papers

6,230
citations

94433

37
h-index

74163

75
g-index

213
all docs

213
docs citations

213
times ranked

7004
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
2	Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting. <i>Neuro-Oncology Practice</i> , 2022, 9, 183-192.	1.6	2
3	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
4	A Combined Biomarker of Bright CD38 and MYC $\geq 55\%$ Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 338-344.	0.7	4
5	Treatment Patterns, Outcomes and the Impact of Cellular Therapies in Secondary Central Nervous System Lymphoma (SCNSL): The UT Southwestern Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S417-S418.	1.2	0
6	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. <i>Expert Review of Hematology</i> , 2022, 15, 321-331.	2.2	7
7	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 487.e1-487.e7.	1.2	4
8	NCCN Guidelines [®] Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	4.9	33
9	Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	7
10	International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. <i>Blood Advances</i> , 2022, 6, 5516-5525.	5.2	11
11	Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 1608-1615.	3.5	12
12	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	1.4	40
13	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 716-721.	1.3	3
14	The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. <i>Leukemia Research</i> , 2021, 100, 106480.	0.8	5
15	Contemporary utilization patterns and outcomes of thrombolytic administration for ischemic stroke among patients with cancer. <i>International Journal of Stroke</i> , 2021, 16, 150-162.	5.9	12
16	Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e865-e875.	0.4	13
17	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
18	Identification of Barriers of CAR-T Utilization in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1972-1972.	1.4	0

#	ARTICLE	IF	CITATIONS
19	T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy. <i>Blood</i> , 2021, 138, 4798-4798.	1.4	1
20	Single-Agent Rituximab and Ultra-Low-Dose Adaptive Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 4510-4510.	1.4	1
21	Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells. <i>Blood</i> , 2021, 138, 4801-4801.	1.4	0
22	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , 2021, 138, 392-392.	1.4	15
23	Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies. <i>Blood</i> , 2021, 138, 4015-4015.	1.4	0
24	COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies. <i>Blood</i> , 2021, 138, 4134-4134.	1.4	2
25	Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort. <i>Blood</i> , 2021, 138, 1217-1217.	1.4	1
26	Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia. <i>Supportive Care in Cancer</i> , 2020, 28, 1799-1807.	2.2	9
27	Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. <i>Blood Advances</i> , 2020, 4, 4860-4863.	5.2	14
28	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
29	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 1039-1046.	2.2	3
30	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3
31	Cardio-Oncology: A Win-Win Situation. <i>Circulation</i> , 2020, 142, 2456-2458.	1.6	11
32	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2020, 75, 620-628.	2.8	49
33	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	1.4	130
34	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 320-329.	3.8	16
35	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
36	CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy. <i>Blood</i> , 2020, 136, 22-23.	1.4	1

#	ARTICLE	IF	CITATIONS
37	The Association of Leukocyte Immunoglobulin-like Receptor B4 (LILRB-4) with Central Nervous System Involvement in Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S111.	2.0	0
38	Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
39	A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL). <i>Blood</i> , 2020, 136, 29-30.	1.4	1
40	Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
41	Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System. <i>Blood</i> , 2020, 136, 11-12.	1.4	0
42	Highlights in chronic lymphocytic leukemia from the 61st American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 3, 14-17.	0.3	0
43	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	23
44	Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. <i>British Journal of Haematology</i> , 2019, 185, 363-366.	2.5	22
45	Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. <i>Resuscitation</i> , 2019, 142, 30-37.	3.0	14
46	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 2019, , 185-190.		1
47	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 399-402.	2.5	10
48	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
49	Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model. <i>Annals of Behavioral Medicine</i> , 2019, 53, 839-848.	2.9	4
50	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia</i> , 2019, 33, 2527-2530.	7.2	65
51	Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. <i>Circulation</i> , 2019, 139, 2594-2596.	1.6	31
52	Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e123-e128.	0.4	1
53	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019, 3, 1553-1562.	5.2	145
54	Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i> , 2019, 134, 1919-1928.	1.4	155

#	ARTICLE	IF	CITATIONS
55	Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. <i>Blood Advances</i> , 2019, 3, 447-460.	5.2	42
56	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1972-1977.	1.3	29
57	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. <i>Blood</i> , 2019, 134, 3045-3045.	1.4	1
58	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	1.4	1
59	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	1.4	3
60	Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4724-4724.	1.4	0
61	Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting. <i>Blood</i> , 2019, 134, 2810-2810.	1.4	2
62	Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team. <i>Blood</i> , 2019, 134, 5878-5878.	1.4	0
63	Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL. <i>Blood</i> , 2019, 134, 1759-1759.	1.4	0
64	Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4082-4082.	1.4	1
65	GEOGRAPHIC TONGUE INDUCED BY VENETOCLAX IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 11.	0.1	6
66	Choosing ibrutinib wisely. <i>Blood</i> , 2018, 131, 156-157.	1.4	0
67	A single-institution retrospective cohort study of first-line EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	2.5	53
68	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. <i>Blood Reviews</i> , 2018, 32, 159-166.	5.7	8
69	Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1631-1634.	1.8	3
70	Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. <i>Journal of the American College of Cardiology</i> , 2018, 72, 697-698.	2.8	80
71	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018, 103, 1351-1358.	3.5	49
72	Use of acalabrutinib in patients with mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 495-502.	2.2	9

#	ARTICLE	IF	CITATIONS
73	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , 2018, 8, 1300-1315.	9.4	115
74	Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies. <i>Blood</i> , 2018, 132, 4423-4423.	1.4	1
75	Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 693-693.	1.4	15
76	A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2018, 132, 3136-3136.	1.4	5
77	Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4185-4185.	1.4	1
78	Depth of response and progression free survival in CLL patients on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7514-7514.	1.6	2
79	Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7528-7528.	1.6	1
80	Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma. <i>Blood</i> , 2018, 132, 5322-5322.	1.4	0
81	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	1.4	1
82	Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment. <i>Blood</i> , 2018, 132, 3148-3148.	1.4	0
83	<i>BTK</i> ^{C481S} -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1437-1443.	1.6	367
84	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e114-e126.	4.6	181
85	Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 618-628.	2.5	36
86	Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1584-1588.	5.2	33
87	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	5.2	123
88	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017, 127, 3052-3064.	8.2	280
89	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , 2017, 130, 830-830.	1.4	27
90	Phase 1b trial of the <i>PI3K</i> / <i>mTOR</i> inhibitor voxtalisib (<i>SAR</i> 245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. <i>British Journal of Haematology</i> , 2016, 175, 55-65.	2.5	12

#	ARTICLE	IF	CITATIONS
91	Cure for CLL?. Blood, 2016, 127, 274-274.	1.4	5
92	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Practice and Research in Clinical Haematology, 2016, 29, 54-66.	1.7	7
93	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
94	Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncolmunology, 2016, 5, e1226720.	4.6	105
95	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Hematology, 2016, 9, 1177-1187.	2.2	2
96	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. Annals of Hematology, 2016, 95, 1137-1143.	1.8	31
97	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. New England Journal of Medicine, 2016, 374, 2530-2541.	27.0	383
98	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2016, 374, 323-332.	27.0	785
99	DNA Hypomethylation within B-Cell Enhancers and Super Enhancers Reveal a Dependency on Immune and Metabolic Mechanisms in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 1049-1049.	1.4	5
100	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. Blood, 2016, 128, 2040-2040.	1.4	2
101	Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway. Blood, 2016, 128, 3225-3225.	1.4	4
102	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. Blood, 2016, 128, 3238-3238.	1.4	5
103	Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2016, 128, 4372-4372.	1.4	1
104	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. Blood, 2016, 128, 4385-4385.	1.4	2
105	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. Blood, 2016, 128, 4386-4386.	1.4	2
106	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. Blood, 2016, 128, 4387-4387.	1.4	8
107	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. Blood, 2016, 128, 4388-4388.	1.4	2
108	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. Blood, 2016, 128, 55-55.	1.4	8

#	ARTICLE	IF	CITATIONS
109	Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study. <i>Blood</i> , 2016, 128, 638-638.	1.4	23
110	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	1.4	22
111	Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. <i>Oncotarget</i> , 2016, 7, 40558-40570.	1.8	30
112	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	1.4	0
113	Analysis of an Online Decision Support Tool for Chronic Lymphocytic Leukemia: Disparities in Treatment Selection Between Experts and Community Practitioners. <i>Blood</i> , 2016, 128, 5958-5958.	1.4	0
114	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. <i>Blood</i> , 2016, 128, 2767-2767.	1.4	0
115	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	1.4	19
116	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2834-2840.	1.3	13
117	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
118	Phase I Trial of the Pan-PI3K Inhibitor Piliarisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 3160-3169.	7.0	51
119	Otlertuzumab (TRU 016), an anti-CD 37 monospecific ADAPTIR [®] therapeutic protein, for relapsed or refractory NHL patients. <i>British Journal of Haematology</i> , 2015, 168, 38-45.	2.5	33
120	Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 425-432.	0.9	6
121	Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 1-12.e7.	0.4	13
122	Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1289-1289.	1.4	1
123	Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. <i>Blood</i> , 2015, 126, 1744-1744.	1.4	2
124	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	1.4	10
125	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953.	1.4	2
126	RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 14632-14645.	1.8	19

#	ARTICLE	IF	CITATIONS
127	Abstract 2191: Transcriptome analysis demonstrates the ability of the bromodomain inhibitor JQ1 to attenuate expression of common oncogenes heterogeneously expressed among chronic lymphocytic leukemia subsets. , 2015, , .		0
128	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. Blood, 2015, 126, 318-318.	1.4	0
129	Administration of anti-thymocyte globulin: a comparison of two protocols. Bone Marrow Transplantation, 2014, 49, 1535-1537.	2.4	5
130	New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms. Clinical Cancer Research, 2014, 20, 5869-5874.	7.0	45
131	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2014, 167, 466-477.	2.5	30
132	Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 343-355.e6.	0.4	15
133	Administration of Rabbit Anti-Thymocyte Globulin: Slowing Infusion Rate over a 4 Day Course with Aggressive Use of Pre-Medications May Decrease ATG Related Infusion Reactions. Biology of Blood and Marrow Transplantation, 2014, 20, S287-S288.	2.0	0
134	PKC- β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood, 2014, 124, 1481-1491.	1.4	45
135	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood, 2014, 124, 3553-3560.	1.4	56
136	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood, 2014, 123, 1302-1308.	1.4	62
137	Ibrutinib: targeting the hidden CLL. Blood, 2014, 123, 3215-3216.	1.4	1
138	Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib. Blood, 2014, 124, 1997-1997.	1.4	3
139	Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study. Blood, 2014, 124, 329-329.	1.4	3
140	Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 4671-4671.	1.4	2
141	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Blood, 2014, 124, 636-636.	1.4	15
142	Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.. Journal of Clinical Oncology, 2014, 32, 7010-7010.	1.6	5
143	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. Journal of Clinical Oncology, 2014, 32, 8506-8506.	1.6	11
144	Obinutuzumab may chart the way to improved QOL for CLL patients. Journal of Community and Supportive Oncology, 2014, 12, 113-114.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Abstract 5182: Identifying differential gene expression and splicing events in chronic lymphocytic leukemia patients through whole transcriptome profiling. , 2014, , .		0
146	Abstract 5180: Profiling signaling pathways in chronic lymphocytic leukemia using reverse phase protein array. , 2014, , .		0
147	Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients. Blood, 2014, 124, 3552-3552.	1.4	0
148	Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka) Tj ETQq0 0 0 rgBT /Overlock 10 Lymphocytic Lymphoma (SLL). Blood, 2014, 124, 1993-1993.	1.4	2
149	Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplantation, 2013, 48, 1279-1284.	2.4	43
150	Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapyâ€era with plerixafor and Gâ€CSF has superior efficacy but significantly higher costs compared to mobilization with lowâ€dose cyclophosphamide and Gâ€CSF. Journal of Clinical Apheresis, 2013, 28, 359-367.	1.3	25
151	Etoposide-induced posterior reversible encephalopathy syndrome. Annals of Hematology, 2013, 92, 561-562.	1.8	8
152	A Multicenter Analysis of Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor for PB Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies. Biology of Blood and Marrow Transplantation, 2013, 19, S182-S183.	2.0	0
153	Intravenous Busulfan Pharmacokinetics in Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Dosing Weight. Biology of Blood and Marrow Transplantation, 2013, 19, S373-S374.	2.0	0
154	Romiplostim resistance in secondary failure of platelet recovery. Journal of Oncology Pharmacy Practice, 2013, 19, 369-372.	0.9	10
155	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. Blood, 2013, 122, 106-106.	1.4	6
156	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2860-2860.	1.4	5
157	Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkinâ€™s Lymphoma Patients. Blood, 2013, 122, 4170-4170.	1.4	8
158	Efficacy and Safety Of Treatments For Relapsed Or Refractory DLBCL: Results Of a Systematic Literature Review. Blood, 2013, 122, 5104-5104.	1.4	1
159	Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.. Journal of Clinical Oncology, 2013, 31, 7091-7091.	1.6	0
160	Congestive heart failure (CHF) in acute myeloid leukemia patients during induction.. Journal of Clinical Oncology, 2013, 31, 7105-7105.	1.6	1
161	Congestive Heart Failure (CHF) During Induction In ACUTE Promyelocytic Leukemia (APL) Patients. Blood, 2013, 122, 3898-3898.	1.4	0
162	Serum Alkaline Phosphatase Level On Day 4 Of G-CSF Administration Could Be a Simple Yet Practical Surrogate Marker For CD34 Mobilization and Collection. Blood, 2013, 122, 4519-4519.	1.4	0

#	ARTICLE	IF	CITATIONS
163	A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US. <i>Blood</i> , 2013, 122, 5597-5597.	1.4	1
164	Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR _α , _β Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 4165-4165.	1.4	1
165	Efficacy and Safety Of Treatments For Relapsed Or Refractory Mantle Cell Lymphoma (MCL): Results Of a Systematic Literature Review. <i>Blood</i> , 2013, 122, 5099-5099.	1.4	0
166	Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 146-148.	2.4	5
167	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1128-1135.	2.0	59
168	Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. <i>Journal of Oncology</i> , 2012, 2012, 1-5.	1.3	9
169	Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2012, 7, 567-578.	2.7	85
170	Phase 1b Study of TRU-016, an Anti-CD37 SMIP _α , _β Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1795-1795.	1.4	2
171	Final Results of a Phase I Study of the Fc Engineered CD19 Antibody XmAb [®] 5574 (MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).. <i>Blood</i> , 2012, 120, 2894-2894.	1.4	2
172	DNA Hypomethylation Leads to Aberrant Expression of PD-1 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3504-3504.	1.4	1
173	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012, 120, 799-799.	1.4	19
174	Genome-Wide DNA Methylation Landscape Defines IGHV Mutated and Unmutated B Cell Chronic Lymphocytic Leukemias. <i>Blood</i> , 2012, 120, 526-526.	1.4	0
175	Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies â€œ A Multicenter Analysis. <i>Blood</i> , 2012, 120, 4409-4409.	1.4	0
176	A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL). <i>Blood</i> , 2012, 120, 4317-4317.	1.4	40
177	Optimizing the Efficacy of Plerixafor as a Salvage Option Inâ€œPoor Mobilizers Following Chemotherapy Plus G-CSF Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S208-S209.	2.0	1
178	Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. <i>Blood</i> , 2011, 118, 2683-2683.	1.4	3
179	Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. <i>Blood</i> , 2011, 118, 4468-4468.	1.4	0
180	Phase 1 Study of TRU-016, An Anti-CD37 SMIP _α , _β Protein in Relapsed and/or Refractory NHL Patients. <i>Blood</i> , 2011, 118, 1636-1636.	1.4	2

#	ARTICLE	IF	CITATIONS
181	Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis. <i>Blood</i> , 2011, 118, 313-313.	1.4	0
182	Phase 1 Study of Tru-016, An Anti-CD37 SMIP α , β Protein in Naïve and Relapsed and/or Refractory CLL Patients. <i>Blood</i> , 2011, 118, 1792-1792.	1.4	2
183	Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. <i>Hematological Oncology</i> , 2010, 28, 3-12.	1.7	9
184	Malignant Thymoma With Immunodeficiency (Good Syndrome) Associated With Mucormycosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 109.	1.3	4
185	CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. <i>Blood</i> , 2010, 115, 1204-1213.	1.4	112
186	How we approach patient evaluation for hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1259-1268.	2.4	71
187	Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 1658-1660.	2.4	6
188	Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 27-38.	1.3	26
189	Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis. <i>Blood</i> , 2010, 116, 1351-1351.	1.4	0
190	Utility of Plerixafor In Addition to Chemotherapy and G-CSF Mobilization Regimens. <i>Blood</i> , 2010, 116, 4443-4443.	1.4	0
191	Allogeneic Transplantation Following Reduced Intensity Conditioning with Fludarabine and Melphalan In Patients with Advanced Myelofibrosis Is Associated with Unacceptable Rates of Acute Graft-Vs-Host Disease and Non-Relapse Mortality.. <i>Blood</i> , 2010, 116, 4552-4552.	1.4	0
192	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. <i>Blood</i> , 2009, 113, 535-537.	1.4	61
193	CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.. <i>Blood</i> , 2009, 114, 3725-3725.	1.4	0
194	Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 480-483.	2.0	38
195	Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 556-567.	2.0	34
196	Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2519-2525.	1.6	144
197	Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1893-1898.	1.3	10
198	The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. <i>Blood</i> , 2008, 111, 3901-3902.	1.4	42

#	ARTICLE	IF	CITATIONS
199	Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.. Blood, 2008, 112, 2105-2105.	1.4	0
200	Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?. Journal of Oncology Pharmacy Practice, 2007, 13, 69-75.	0.9	22
201	Gastrointestinal chronic graft-versus-host disease: management options. Journal of Oncology Pharmacy Practice, 2007, 13, 49-51.	0.9	2
202	Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. American Journal of Hematology, 2007, 82, 1120-1121.	4.1	2
203	Wnt'er in liver: Expression of Wnt and frizzled genes in mouse. Hepatology, 2007, 45, 195-204.	7.3	131
204	Paraneoplastic Sweet's syndrome and the pathergy phenomenon. Annals of Hematology, 2007, 86, 613-614.	1.8	14
205	Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.. Blood, 2007, 110, 4727-4727.	1.4	0
206	High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.. Blood, 2007, 110, 5080-5080.	1.4	0
207	Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect.. Blood, 2007, 110, 3044-3044.	1.4	0
208	Role of thiamine in managing ifosfamide-induced encephalopathy. Journal of Oncology Pharmacy Practice, 2006, 12, 237-239.	0.9	42